SCHEMBL2350106

SCHEMBL2350106

COc1cc(OC(=O)c2cccnc2)ccc1-c1ccc2c(c1C(O)Cc1ccc(Br)s1)C(C)=CC(C)(C)N2

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
TP53 P04637 2/20 0.56
MAPT P10636 2/20 0.56
HTT P42858 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NR3C1 P04150 14/20 0.37
NR3C2 P08235 2/20 0.37
AR P10275 2/20 0.37
KMT2A Q03164 3/20 0.36
PGR P06401 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350973 0.88 MAPT (0.55) LMNATP53MAPTHTTNPSR1
SCHEMBL2350101 0.86 MAPT (0.57) LMNATP53MAPTHTTNPSR1
SCHEMBL2349558 0.85 MAPT (0.46) LMNATP53MAPTHTTNPSR1
SCHEMBL2355752 0.85 MAPT (0.39) LMNATP53MAPTHTTNPSR1
SCHEMBL2354784 0.85 MAPT (0.44) LMNATP53MAPTHTTNPSR1
SCHEMBL1782503 0.82 LMNA (0.57) LMNATP53MAPTHTTNPSR1
SCHEMBL2355734 0.81 PGR (0.43) NR3C1NR3C2ARPGR
SCHEMBL1314233 0.80 LMNA (0.62) LMNATP53MAPTHTTNPSR1
SCHEMBL2351050 0.80 MAPT (0.39) LMNATP53MAPTHTTNPSR1
SCHEMBL2350297 0.79 HTT (0.41) LMNATP53MAPTHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008497-B2 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-08-30 US disclosed
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298826-A1 NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS NR3C1, NR3C2, NR5A1 LMNA 4460/4885TP53 4197/4885MAPT 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.